Results 131 to 140 of about 748,749 (317)

Investigation on the therapeutic potential of the placebo effect open label

reservedIl presente elaborato indaga l’efficacia del placebo open label, trattamento attraverso il quale in modo consapevole e dichiarato vengono somministrati ai pazienti sostanze prive di principio attivo ma che producono comunque dei miglioramenti ...
ACCARDO, FRANCESCO LORENZO
core  

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

American Journal of Hematology, EarlyView.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos   +49 more
wiley   +1 more source

Integrating Genetic Modifier Genotype With Serum Proteomics in Duchenne Muscular Dystrophy Clinical Trials Links LTBP4 Genetic Modifier to IL‐23/CD93 Pathways in Muscle

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Genetic modifiers of Duchenne muscular dystrophy (DMD) that alter disease severity or response to therapy have been reported using natural history or registry data sets of older corticosteroid‐treated patients. We tested associations of genetic modifiers on motor function outcomes in young (4 to < 7 years) steroid naïve clinical trial ...
Utkarsh J. Dang, Yuan Fang, Daniele Sabbatini, Elena Pegoraro, Luca Bello, Paula R. Clemens, Michela Guglieri, John van den Anker, Jesse Damsker, Laura Hagerty, Yetrib Hathout, Michael Ziemba, Lauren Morgenroth, Surajit Bhattacharya, Kanneboyina Nagaraju, Jyoti K. Jaiswal, Eric P. Hoffman   +16 more
wiley   +1 more source

Placebo or no placebo? [PDF]

Nature, 1990
openaire   +1 more source

The placebo effect

, 2018
“Placebo: a usually pharmacologically inert preparation prescribed more for the mental relief of the patient than for its actual effect on a disorder” – Merriam-Webster Medical Dictionary Everyone has heard of placebos, but have we ever wondered ...
Ismawi, Hidayatul Radziah
core  

Lost and Found: Is Olfactory Recovery More Promising After COVID‐19 Than Other Causes, Even 2 Years Later?

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker, Mabel Berg, Nicolaus Knight, Jessica W. Grayson, Bradford A. Woodworth, Justin H. Turner, Do‐Yeon Cho   +6 more
wiley   +1 more source

Placebo-controlled trial of misoprostol in cystic fibrosis

, 1990
Placebo-controlled trial of misoprostol in cystic ...
P Robinson (12067037), PD Sly (14453628)
core  

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu, Houyong Li, Xicai Sun, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang   +9 more
wiley   +1 more source

Effect of Remifentanil on Intra-Ocular Pressure in Cataract Surgery under General Anesthesia with Isoflurane

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2009
BACKGROUND AND OBJECTIVE: One of the important aims in anesthetic management during ocular surgery is to provide adequate control of intraocular pressure (IOP) and increasing of this pressure would cause some dramatic complications even though visual ...
MR Ghodrati,, A Shakeri, N Farnoush, A Shakeri,   +3 more
doaj  

Inflammatory Signatures Beyond Th1/Th2 Endotypes Provide Insights Into Postoperative Recurrence in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel, Narin N. Carmel, Shaun Edalati, Hen Chaushu, Forsan Jahshan, Yaniv Hadi, Timur Pestrikov, Leonor Leider Trejo, Nidal Muhanna, Avraham Abergel   +9 more
wiley   +1 more source